Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 36, Issue 3, 2009, Pages 343-346

  Verburg, Frederik A ^a   Dietlein, Markus ^b   Lassmann, Michael ^a   Luster, Markus ^c   Reiners, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Ablation; Endocrinology; Oncology; Radioiodine; Radionuclide therapy; Thyroid carcinoma

Indexed keywords

IODINE 131; RADIOACTIVE IODINE; THYROGLOBULIN;

DIFFERENTIATED THYROID CARCINOMA; DRUG EFFECT; DRUG SAFETY; EDITORIAL; HUMAN; LACRIMAL DUCT DAMAGE; LACRIMAL GLAND DISEASE; RADIATION ABSORPTION; RADIOACTIVITY; SIALOADENITIS; STOMATITIS; THYROID CARCINOMA; THYROIDECTOMY; TREATMENT OUTCOME;

CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; HUMANS; IODINE RADIOISOTOPES; NEOPLASM STAGING; THYROID NEOPLASMS;

EID: 60549096079     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0997-5     Document Type: Editorial

References (42)

1. ID Hay IR McDougall JC Sisson 2008 Perspective: the case against radioiodine remnant ablation in patients with well-differentiated thyroid carcinoma J Nucl Med 49 1395 1397
2. AM Sawka DP Goldstein L Thabane JD Brierley RW Tsang L Rotstein 2008 Basis for physician recommendations for adjuvant radioiodine therapy in early-stage thyroid carcinoma: principal findings of the Canadian-American thyroid cancer survey Endocr Pract 14 175 184
3. DS Cooper GM Doherty BR Haugen RT Kloos SL Lee SJ Mandel 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer Thyroid 16 109 142
4. F Pacini M Schlumberger H Dralle R Elisei JW Smit W Wiersinga 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium Eur J Endocrinol 154 787 803
5. M Luster SE Clarke M Dietlein M Lassmann P Lind WJ Oyen 2008 Guidelines for radioiodine therapy of differentiated thyroid cancer Eur J Nucl Med Mol Imaging 35 1941 1959
6. M Dietlein J Dressler W Eschner F Grünwald M Lassmann B Leisner 2007 Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3) Nuklearmedizin 46 213 219
7. M Dietlein J Dressler W Eschner F Grünwald M Lassmann B Leisner 2007 Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 3) Nuklearmedizin 46 206 212
8. MJ Schlumberger 1998 Papillary and follicular thyroid carcinoma N Engl J Med 338 297 306
9. EL Mazzaferri SM Jhiang 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer Am J Med 97 418 428
10. EL Mazzaferri RT Kloos 2001 Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer J Clin Endocrinol Metab 86 1447 1463
11. M Tubiana M Schlumberger P Rougier A Laplanche E Benhamou P Gardet 1985 Long-term results and prognostic factors in patients with differentiated thyroid carcinoma Cancer 55 794 804
12. WJ Simpson T Panzarella JS Carruthers MK Gospodarowicz SB Sutcliffe 1988 Papillary and follicular thyroid cancer: impact of treatment in 1578 patients Int J Radiat Oncol Biol Phys 14 1063 1075
13. RD Utiger 1997 Follow-up of patients with thyroid carcinoma N Engl J Med 337 928 930
14. SI Sherman ET Tielens S Sostre MD Wharam Jr PW Ladenson 1994 Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma J Clin Endocrinol Metab 78 629 634
15. F Tenenbaum C Corone M Schlumberger C Parmentier 1996 Thyroglobulin measurement and postablative iodine-131 total body scan after total thyroidectomy for differentiated thyroid carcinoma in patients with no evidence of disease Eur J Cancer 32A 1262
16. JP Travagli AF Cailleux M Ricard E Baudin C Parmentier M Schlumberger 1998 Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma J Clin Endocrinol Metab 83 2675 2680
17. J Jonklaas NJ Sarlis D Litofsky KB Ain ST Bigos JD Brierley 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy Thyroid 16 1229 1242
18. A Machens HJ Holzhusen H Dralle 2005 The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. A comparative analysis Cancer 103 2269 2273
19. AM Sawka JD Brierley RW Tsang L Thabane L Rotstein A Gafni 2008 An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer Endocrinol Metab Clin North Am 37 457 480
20. TM Shattuck WH Westra PW Ladenson A Arnold 2005 Independent clonal origins of distinct tumor foci in multifocal papillary thyroid carcinoma N Engl J Med 352 2406 2412
21. F Pacini M Schlumberger C Harmer GG Berg O Cohen L Duntas 2005 Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report Eur J Endocrinol 153 651 659
22. M Schlumberger G Berg O Cohen L Duntas F Jamar B Jarzab 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective Eur J Endocrinol 150 105 112
23. FA Verburg B de Keizer CJ Lips PM Zelissen JM de Klerk 2005 Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients Eur J Endocrinol 152 33 37
24. ID Hay CS Grant WF Taylor WM McConahey 1987 Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system Surgery 102 1088 1095
25. ID Hay CS Grant EJ Bergstralh GB Thompson JA van Heerden JR Goellner 1998 Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma Surgery 124 958 964
26. ID Hay 2006 Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular carcinoma J Surg Oncol 94 692 700
27. S Hölzer C Reiners K Mann M Bamberg M Rothmund J Dudeck 2000 Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group Cancer 89 192 201
28. R Solans JA Bosch P Galofre F Porta J Roselló A Selva-O'Callagan 2001 Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy J Nucl Med 42 738 743
29. EB Silberstein 2008 Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine J Nucl Med 49 546 549
30. RT Kloos V Duvuuri SM Jhiang KV Cahill JA Foster JA Burns 2002 Nasolacrimal drainage obstruction from radioactive iodine therapy for thyroid carcinoma J Clin Endocrinol Metab 87 5817 5820
31. SM Seidlin E Siegal AA Yalow S Melamed 1956 Acute myeloid leukemia following prolonged iodine-131 therapy for metastatic thyroid carcinoma Science 123 800 801
32. SM Seidlin E Siegel S Melamed AA Yalow 1955 Occurrence of myeloid leukemia in patients with metastatic thyroid carcinoma following prolonged massive radioiodine therapy Bull N Y Acad Med 31 410
33. SM Seidlin AA Yalow E Siegel 1954 Blood radiation dose during radioiodine therapy of metastatic thyroid carcinoma Radiology 63 797 813
34. CM Ronckers P McCarron E Ron 2005 Thyroid cancer and multiple primary tumors in the SEER cancer registries Int J Cancer 117 281 288
35. AP Brown J Chen YJ Hitchcock A Szabo DC Shrieve JD Tward 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer J Clin Endocrinol Metab 93 504 515
36. C Rubino F de Vathaire ME Dottorini P Hall C Schvartz JE Couette 2003 Second primary malignancies in thyroid cancer patients Br J Cancer 89 1638 1644
37. RB Verkooijen JW Smit JA Romijn MP Stokkel 2006 The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer Eur J Endocrinol 155 801 806
38. N Bhattacharyya W Chien 2006 Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma Ann Otol Rhinol Laryngol 115 607 610
39. H Hänscheid M Lassmann M Luster M Luster SR Thomas F Pacini 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal J Nucl Med 47 648 654
40. RD Leeper 1973 The effect of 131I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma J Clin Endocrinol Metab 36 1143 1152
41. M Lassmann H Hänscheid C Chiesa C Hindorf G Flux M Luster 2008 EANM dosimetry committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy Eur J Nucl Med Mol Imaging 35 1405 1412
42. C Dragoiescu OS Hoekstra DJ Kuik P Lips MA Plaizier PT Rodrigus 2003 Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer Clin Endocrinol 58 451 455